Bert Christoph, Graeff Christian, Riboldi Marco, Nill Simeon, Baroni Guido, Knopf Antje-Christin
University Clinic Erlangen, Radiation Oncology, Universitatsstrasse 27, 91054 Erlangen, Germany.
Technol Cancer Res Treat. 2014 Dec;13(6):485-95. doi: 10.7785/tcrtexpress.2013.600274. Epub 2013 Dec 17.
We report on recent progress in the field of mobile tumor treatment with scanned particle beams, as discussed in the latest editions of the 4D treatment planning workshop. The workshop series started in 2009, with about 20 people from 4 research institutes involved, all actively working on particle therapy delivery and development. The first workshop resulted in a summary of recommendations for the treatment of mobile targets, along with a list of requirements to apply these guidelines clinically. The increased interest in the treatment of mobile tumors led to a continuously growing number of attendees: the 2012 edition counted more than 60 participants from 20 institutions and commercial vendors. The focus of research discussions among workshop participants progressively moved from 4D treatment planning to complete 4D treatments, aiming at effective and safe treatment delivery. Current research perspectives on 4D treatments include all critical aspects of time resolved delivery, such as in-room imaging, motion detection, beam application, and quality assurance techniques. This was motivated by the start of first clinical treatments of hepato cellular tumors with a scanned particle beam, relying on gating or abdominal compression for motion mitigation. Up to date research activities emphasize significant efforts in investigating advanced motion mitigation techniques, with a specific interest in the development of dedicated tools for experimental validation. Potential improvements will be made possible in the near future through 4D optimized treatment plans that require upgrades of the currently established therapy control systems for time resolved delivery. But since also these novel optimization techniques rely on the validity of the 4DCT, research focusing on alternative 4D imaging technique, such as MRI based 4DCT generation will continue.
我们报告了扫描粒子束移动肿瘤治疗领域的最新进展,这在最新版的4D治疗计划研讨会上进行了讨论。该研讨会系列始于2009年,约有来自4个研究机构的20人参与,他们都积极致力于粒子治疗的输送和开发。第一次研讨会总结了移动靶标治疗的建议,并列出了在临床应用这些指南的要求清单。对移动肿瘤治疗兴趣的增加导致参会人数不断增加:2012年的研讨会有来自20个机构和商业供应商的60多名参与者。研讨会参与者之间的研究讨论重点逐渐从4D治疗计划转向完整的4D治疗,旨在实现有效和安全的治疗输送。当前关于4D治疗的研究视角包括时间分辨输送的所有关键方面,如室内成像、运动检测、束流应用和质量保证技术。这是由肝细胞肿瘤的首次扫描粒子束临床治疗的开始所推动的,该治疗依靠门控或腹部压迫来减轻运动。最新的研究活动强调在研究先进的运动减轻技术方面做出了重大努力,特别关注开发用于实验验证的专用工具。通过4D优化治疗计划,在不久的将来可能会实现潜在的改进,这需要升级当前已建立的用于时间分辨输送的治疗控制系统。但由于这些新颖的优化技术也依赖于4DCT的有效性,因此专注于替代4D成像技术(如基于MRI的4DCT生成)的研究将继续进行。